Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 118

1.

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption.

Park YJ, Etemad B, Ahmed H, Naranbhai V, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Carrington M, Li JZ.

Pathog Immun. 2017;2(3):431-445. doi: 10.20411/pai.v2i3.222. Epub 2017 Nov 27.

2.

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.

Thomas AS, Jones KL, Gandhi RT, McMahon DK, Cyktor JC, Chan D, Huang SH, Truong R, Bosque A, Macedo AB, Kovacs C, Benko E, Eron JJ, Bosch RJ, Lalama CM, Simmens S, Walker BD, Mellors JW, Jones RB.

PLoS Pathog. 2017 Sep 20;13(9):e1006629. doi: 10.1371/journal.ppat.1006629. eCollection 2017 Sep.

3.

Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation.

Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW; ACTG A5321 Team.

PLoS Pathog. 2017 Apr 20;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. eCollection 2017 Apr.

4.

Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A5275).

Nixon DE, Bosch RJ, Chan ES, Funderburg NT, Hodder S, Lake JE, Lederman MM, Klingman KL, Aberg JA; AIDS Clinical Trials Group Study A5275 Team.

J Clin Lipidol. 2017 Jan - Feb;11(1):61-69. doi: 10.1016/j.jacl.2016.09.017. Epub 2016 Oct 5.

5.

Maternal Antiretroviral Therapy Is Associated with Lower Risk of Diarrhea in Early Childhood.

Sztam KA, Liu E, Manji KP, Kupka R, Kisenge R, Aboud S, Fawzi WW, Bosch RJ, Duggan CP.

J Pediatr. 2016 Aug;175:54-60. doi: 10.1016/j.jpeds.2016.04.088. Epub 2016 May 28.

6.

Innate immune reconstitution with suppression of HIV-1.

Scully EP, Lockhart A, Garcia-Beltran W, Palmer CD, Musante C, Rosenberg E, Allen TM, Chang JJ, Bosch RJ, Altfeld M.

JCI Insight. 2016 Mar 17;1(3):e85433.

7.

Brief Report: Relationship Among Viral Load Outcomes in HIV Treatment Interruption Trials.

Treasure GC, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Para M, Gandhi RT, Li JZ.

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):310-3. doi: 10.1097/QAI.0000000000000964.

8.

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.

Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT.

AIDS. 2016 Jan 28;30(3):343-53. doi: 10.1097/QAD.0000000000000953.

9.

CCR5-Δ32 Heterozygosity, HIV-1 Reservoir Size, and Lymphocyte Activation in Individuals Receiving Long-term Suppressive Antiretroviral Therapy.

Henrich TJ, Hanhauser E, Harrison LJ, Palmer CD, Romero-Tejeda M, Jost S, Bosch RJ, Kuritzkes DR.

J Infect Dis. 2016 Mar 1;213(5):766-70. doi: 10.1093/infdis/jiv504. Epub 2015 Oct 28.

10.

Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1-Infected Men.

Scully E, Lockhart A, Huang L, Robles Y, Becerril C, Romero-Tejeda M, Albrecht MA, Palmer CD, Bosch RJ, Altfeld M, Kuritzkes DR, Lin NH.

J Infect Dis. 2016 Mar 1;213(5):771-5. doi: 10.1093/infdis/jiv501. Epub 2015 Oct 22.

11.

HLA Class I Alleles Associated with Mortality in Thai Military Recruits with HIV-1 CRF01_AE Infection.

Gandhi RT, Bosch RJ, Rangsin R, Chuenchitra T, Sirisopana N, Kim JH, Robb ML, Vejbaesya S, Paris RM, Nelson KE.

AIDS Res Hum Retroviruses. 2016 Jan;32(1):44-9. doi: 10.1089/aid.2015.0120. Epub 2015 Sep 18.

12.

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir.

Ouyang Z, Buzon MJ, Zheng L, Sun H, Yu XG, Bosch RJ, Mellors JW, Eron JJ, Gandhi RT, Lichterfeld M.

Open Forum Infect Dis. 2015 Apr 1;2(2):ofv045. doi: 10.1093/ofid/ofv045. eCollection 2015 Apr.

13.

Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy.

Riddler SA, Aga E, Bosch RJ, Bastow B, Bedison M, Vagratian D, Vaida F, Eron JJ, Gandhi RT, Mellors JW; ACTG A5276s Protocol Team.

J Infect Dis. 2016 Feb 15;213(4):556-60. doi: 10.1093/infdis/jiv433. Epub 2015 Sep 2.

14.

Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring.

Schnitzer ME, Lok JJ, Bosch RJ.

Biostatistics. 2016 Jan;17(1):165-77. doi: 10.1093/biostatistics/kxv028. Epub 2015 Jul 29.

15.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL, Eron JJ, Margolis DM, Bosch RJ, Archin NM.

J Infect Dis. 2015 Nov 1;212(9):1361-5. doi: 10.1093/infdis/jiv218. Epub 2015 Apr 15.

16.

Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen.

Lee AJ, Bosch RJ, Evans SR, Wu K, Harrison T, Grant P, Clifford DB.

J Neurovirol. 2015 Apr;21(2):210-8. doi: 10.1007/s13365-015-0327-1. Epub 2015 Feb 13.

17.

End-stage renal disease among HIV-infected adults in North America.

Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, Wester CW, Bosch RJ, Crane H, Eron J, Gill MJ, Horberg MA, Justice AC, Klein M, Mayor AM, Moore RD, Palella FJ, Parikh CR, Silverberg MJ, Golub ET, Jacobson LP, Napravnik S, Lucas GM; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA).

Clin Infect Dis. 2015 Mar 15;60(6):941-9. doi: 10.1093/cid/ciu919. Epub 2014 Nov 18.

18.

Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286.

Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, Wilson CC; A5286 Team.

J Infect Dis. 2015 Mar 1;211(5):780-90. doi: 10.1093/infdis/jiu515. Epub 2014 Sep 11.

19.

CD4 trajectory adjusting for dropout among HIV-positive patients receiving combination antiretroviral therapy in an East African HIV care centre.

Kiragga AN, Lok JJ, Musick BS, Bosch RJ, Mwangi A, Wools-Kaloustian KK, Yiannoutsos CT; East Africa IeDEA Regional Consortium.

J Int AIDS Soc. 2014 Aug 14;17:18957. doi: 10.7448/IAS.17.1.18957. eCollection 2014.

20.

HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy.

Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, Riddler SA, McMahon DK, Hong F, Mellors JW.

Clin Infect Dis. 2014 Nov 1;59(9):1312-21. doi: 10.1093/cid/ciu585. Epub 2014 Jul 29.

Supplemental Content

Loading ...
Support Center